SGCB and hydrops fetalis: Investigation of sGC stimulators as a treatment for heart disease has been under investigation for two decades, most recently for the treatment of HF since the sGC‐NO‐cGMP pathway is often disrupted under this pathology [28, 29, 30, 31].